| 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer F Bensch, EL van der Veen, MN Lub-de Hooge, A Jorritsma-Smit, ... Nature medicine 24 (12), 1852-1858, 2018 | 668 | 2018 |
| 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up F Bensch, AH Brouwers, MN Lub-de Hooge, JR de Jong, B van der Vegt, ... European journal of nuclear medicine and molecular imaging 45, 2300-2306, 2018 | 140 | 2018 |
| TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET MW den Hollander, F Bensch, AWJM Glaudemans, THO Munnink, ... Journal of Nuclear Medicine 56 (9), 1310-1314, 2015 | 114 | 2015 |
| HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting A Kol, AGTT van Scheltinga, H Timmer-Bosscha, LE Lamberts, F Bensch, ... Pharmacology & therapeutics 143 (1), 1-11, 2014 | 98 | 2014 |
| ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment LE Lamberts, CW Menke-van der Houven van Oordt, EJ Ter Weele, ... Clinical Cancer Research 22 (7), 1642-1652, 2016 | 84 | 2016 |
| 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors F Bensch, LE Lamberts, MM Smeenk, A Jorritsma-Smit, ... Clinical Cancer Research 23 (20), 6128-6137, 2017 | 78 | 2017 |
| Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers—The first step towards an imaging warehouse F Bensch, MM Smeenk, SC van Es, JR de Jong, CP Schröder, SF Oosting, ... Theranostics 8 (16), 4295, 2018 | 65 | 2018 |
| Molecular imaging to enlighten cancer immunotherapies and underlying involved processes EL van der Veen, F Bensch, AWJM Glaudemans, MN Lub-de Hooge, ... Cancer Treatment Reviews 70, 232-244, 2018 | 52 | 2018 |
| Molecular imaging for monitoring treatment response in breast cancer patients F Bensch, M van Kruchten, LE Lamberts, CP Schröder, GAP Hospers, ... European journal of pharmacology 717 (1-3), 2-11, 2013 | 27 | 2013 |
| Decalcification of breast cancer bone metastases with EDTA does not affect ER, PR, and HER2 results SC Van Es, B van der Vegt, F Bensch, S Gerritse, EJ Van Helden, E Boon, ... The American Journal of Surgical Pathology 43 (10), 1355-1360, 2019 | 24 | 2019 |
| Abstract CT017: First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab F Bensch, E Veen, A Jorritsma, ML Hooge, R Boellaard, S Oosting, ... Cancer research 77 (13_Supplement), CT017-CT017, 2017 | 22 | 2017 |
| Assessment of bone lesions with 18F-FDG PET compared with 99mTc bone scintigraphy leads to clinically relevant differences in metastatic breast Cancer management SC van Es, T Velleman, SG Elias, F Bensch, AH Brouwers, ... Journal of nuclear medicine 62 (2), 177-183, 2021 | 18 | 2021 |
| Safety and efficacy of extended interval dosing for immune checkpoint inhibitors in non–small cell lung cancer during the COVID-19 pandemic LBM Hijmering-Kappelle, TJN Hiltermann, F Bensch Clinical lung cancer 23 (2), 143-150, 2022 | 16 | 2022 |
| Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis YWS Jauw, F Bensch, AH Brouwers, OS Hoekstra, JM Zijlstra, ... European Journal of Nuclear Medicine and Molecular Imaging 46, 1840-1849, 2019 | 16 | 2019 |
| Menke-van der Houven van Oordt, CW; Brouwers, AH; Boellaard, R.; et al F Bensch, MM Smeenk, SC Van Es, JR De Jong, CP Schroder, ... Comparative biodistribution analysis across four different (89) Zr …, 2018 | 14 | 2018 |
| Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors. F Bensch, LE Lamberts, MN Lub-de Hooge, ... Journal of Clinical Oncology 32 (15_suppl), 11095-11095, 2014 | 14 | 2014 |
| 89zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients. MW den Hollander, F Bensch, AWJM Glaudemans, RH Enting, ... Journal of Clinical Oncology 31 (15_suppl), 2050-2050, 2013 | 14 | 2013 |
| Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion–Metastatic breast cancer (MBC) F Bensch, A Brouwers, A Glaudemans, J de Jong, E de Vries, ... Cancer Research 75 (9_Supplement), OT3-2-01-OT3-2-01, 2015 | 9 | 2015 |
| A 21-year-old patient with a HER2-positive colorectal cancer F Bensch, JM van Rooijen, CP Schröder, AKL Reyners Gastroenterology 148 (1), 20-21, 2015 | 8 | 2015 |
| Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic … J Boers, B Eisses, MC Zwager, JJL van Geel, F Bensch, EFJ de Vries, ... Diagnostics 14 (4), 416, 2024 | 5 | 2024 |
Elisabeth de VriesProfessor of Medical Oncology, University Medical Center Groningen, Groningen, the NetherlandsEmail yang diverifikasi di umcg.nl